Navigation Links
Pharmacyclics Reports Fourth Quarter and Full Year Fiscal 2012 Financial Results and Recent Developments
Date:9/5/2012

1759,973* Includes share-based compensation as follows:Research and development

$

1,013

$

1,133

$

6,947

$

5,307General and administrative8357132,9262,511Total

$

1,848

$

1,846

$

9,873

$

7,818 Reconciliation of Selected GAAP Measures to Non-GAAP Measures (1)
(unaudited; in thousands, except per share data) 

Three Months EndedJune 30,20122011GAAP net loss$

(16,906)

$

(10,964)Adjustments:Research & development share-based compensation(2)1,0131,133General & administrative share-based compensation(2)8357131,8481,846Non-GAAP net loss$

(15,058)

$

(9,118)Non-GAAP net loss per share – basic and diluted$

(0.22)

$

(0.15)(1) This presentation includes non-GAAP measures. Our non-GAAP measures are not meant to 
be considered in isolation or as a substitute for comparable GAAP measures and should be
read only in conjunction with our financial statements prepared in accordance with GAAP.(2) All share-based compensation was excluded for the non-GAAP analysis. Reconciliation of Selected GAAP Measures to Non-GAAP Measures (1)
(unaudited; in thousands, except per share data) 

Year Ended June 30,20122011GAAP net income (loss)$

11,986

$

(35,203)Adjustments:Research & development share-based compensation(2)6,9475,307General & administrative share-based compensation(2)2,9262,511Therapeutic discovery project tax grant, net(3)-(586)9,8737,232Non-GAAP net income (loss)$

21,859

$

(27,971)Non-GAAP net income (loss) per share Basic$

0.32

$

(0.47)Diluted$

0.30

$

(0.47)(1) This presentation includes non-GAAP measures. Our n
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology
2. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
3. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
4. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
5. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
6. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012
7. Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter
8. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
9. PAREXEL Reports Third Quarter Fiscal Year 2012 Financial Results
10. Luminex Corporation Reports First Quarter 2012 Results
11. Hospira Reports First-Quarter 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... Calif. , June 19, 2013   ... today announces a licensing agreement granting Suzhou Ribo ... and manufacture siRNA therapeutics in China ...  Ribo will formulate proprietary siRNA molecules in combination ... designed to address human diseases with high unmet ...
(Date:6/19/2013)... 19. Juni 2013 Specialty ... der Entwicklung von SCS microRESIST™, einer ... der Beschichtung mit Parylene gelungen ist. ... biokompatiblem Parylene mit antimikrobiellen Eigenschaften und ... Mikroorganismen auf beschichteten medizinischen Geräten. ...
(Date:6/18/2013)... 2013  Intercept Pharmaceuticals, Inc.  (NASDAQ: ICPT ... development and commercialization of novel bile acid therapeutics to ... an underwritten public offering of 1,730,000 shares of its ... per share.  In addition, Intercept has granted the underwriters ... 259,500 shares of common stock. All of ...
Breaking Medicine Technology:Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 2Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 3Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 4Specialty Coating Systems gibt die Einführung einer neuen antimikrobiellen Parylene-Technologie bekannt 2Intercept Pharmaceuticals Announces Pricing of Public Offering of Common Stock 2
(Date:6/19/2013)... Arbor, Mich. Children had half as many ... evening office hours on five or more days a ... at C.S. Mott Children,s Hospital and Johns Hopkins University. ... in The Journal of Pediatrics and will ... "These findings are an important step in understanding where ...
(Date:6/19/2013)... (PROVIDENCE, R.I.) Casual, no-strings sexual encounters are ... students more likely than others to "hook up"? ... Hospital,s Centers for Behavioral and Preventive Medicine, published ... , suggests there are certain factors and behaviors ... women. , "Given the potential for negative ...
(Date:6/19/2013)... body,s system for repairing damage to the genetic material ... it may seem, those compounds are sparking optimism as ... a mutation in BRCA, a gene that made headlines ... The compounds, termed PARP inhibitors, are the topic of ... Chemical & Engineering News . C&EN is the weekly ...
(Date:6/19/2013)... at Louisiana State University have developed a method for ... relies on understanding the genetic interaction between single nucleotide ... prostate cancer,s aggressiveness to avoid unnecessary radical treatment. ... PLOS ONE in April. , According to ... all cancers and 9 percent of cancer deaths. It ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 Alternatives, a ... some patients to quit using drugs while allowing them ... Jaffe, the founders of Alternatives, believe that abstinence-only approaches ... they enter treatment and that this approach hurts instead ... people in the United States need treatment for addiction ...
Breaking Medicine News(10 mins):Health News:Extended primary care office hours might help keep kids out of the emergency department 2Health News:Why are some college students more likely to 'hook up'? 2Health News:Moffitt Cancer Center researchers identify genetic variants predicting aggressive prostate cancers 2Health News:Top L.A. Addiction Experts Assert That an Abstinence-Only Approach to Addiction Keeps 85% of Addicts From Seeking Treatment 2Health News:Top L.A. Addiction Experts Assert That an Abstinence-Only Approach to Addiction Keeps 85% of Addicts From Seeking Treatment 3
... suggests, , , WEDNESDAY, Jan. 21 (HealthDay News) -- Although ... severe complications, a new report shows the rate of ... Problems such as blood clots, serious breathing difficulties, shock, ... from 0.64 percent in 1998/1999 to 0.81 percent in ...
... Jan. 21, 2009 Joslin Diabetes Center scientists are taking ... diabetes to a new level with the launch of a ... used for years to manage arthritis pain, can reduce blood ... the trial could lead one day to an inexpensive way ...
... Jan. 21 Alliance Tech ( http://alliancetech.com ... RFID, announced today that Carestream Health, Inc., ... to identify additional lead opportunities with attendees ... (RSNA) conference held in Chicago in early ...
... Favorite Body Parts: Our Faces are Fabulous; Tummies ... abs top the list of favorite and least favorite ... to a new survey conducted by American Laser Centers, ... U.S.Nearly a quarter of the men (24 percent) and ...
... ... January 21, 2009 -- Investing in self-improvement will still be a ... the leadership of the Physicians Coalition for Injectable Safety . ... who elect to enhance personal appearance with cosmetic injections. "Despite an ...
... 21 Senator Sam Brownback and Rep. Cathy ... Blogs for Life, on Thursday, ... feature several prominent conservative voices including Amanda Carpenter, ... Michael Illions, Peter Shinn, Chris Gacek, J.D., and ...
Cached Medicine News:Health News:Severe Obstetric Complications on the Increase 2Health News:Severe Obstetric Complications on the Increase 3Health News:Joslin launches national study to explore if anti-inflammatory drug can treat type 2 diabetes 2Health News:Joslin launches national study to explore if anti-inflammatory drug can treat type 2 diabetes 3Health News:Alliance Tech's RFID Technology Enhances Carestream Health's Capability to Connect with Key Prospects at RSNA 2Health News:Alliance Tech's RFID Technology Enhances Carestream Health's Capability to Connect with Key Prospects at RSNA 3Health News:How Does Our Vanity Fare? 2Health News:Cosmetic Injections A Worthwhile Investment 2Health News:Cosmetic Injections A Worthwhile Investment 3Health News:Cosmetic Injections A Worthwhile Investment 4Health News:Senator Sam Brownback and Rep. Cathy McMorris Rodgers to Speak at Blogs for Life 2009 2
Delicate curved shafts with light crisscross serrations. Serrated handle with polished finish. Most popular size or model....
Straight tips with fine 1 x 2 teeth. Serrated handle with polished finish. Most popular size or model....
Straight tubular shaft with delicate 1.5 mm oval jaws. Squeeze barrel style handle with tip guard and polished finish....
Inner jaw space 2.0 mm - 45 degree tip angulation. 20 gauge (.89 mm) diameter shaft and stationary distal jaw. Lightweight squeeze handle with dull finish. Jaws 1.5 mm serrated....
Medicine Products: